Compare ABUS & MYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | MYE |
|---|---|---|
| Founded | 2005 | 1933 |
| Country | United States | United States |
| Employees | N/A | 2200 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 825.9M |
| IPO Year | 2008 | 1995 |
| Metric | ABUS | MYE |
|---|---|---|
| Price | $4.37 | $22.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.7M | 202.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | 55.26 | ★ 389.47 |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | $0.87 |
| Revenue Next Year | $239.71 | $1.83 |
| P/E Ratio | $5.10 | ★ N/A |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.04 | $12.20 |
| 52 Week High | $5.10 | $24.25 |
| Indicator | ABUS | MYE |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 54.49 |
| Support Level | $4.17 | $20.03 |
| Resistance Level | $4.60 | $22.54 |
| Average True Range (ATR) | 0.16 | 0.98 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 61.46 | 56.09 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.